Siemens Healthineers stock: analysis & valuation

SHL.DEMedical DevicesGermanyData as of Nov 15, 2026
Metrics analysis · Medical Devices

Siemens Healthineers SHL.DE

Price 43.95 EUR +0.34%Market cap 49.2 bn EUR52 weeks 32.81 – 47.26
Forward P/E
16.7x
Industry 19.3x
EV/EBITDA
13.9x
Industry 17.3x
Revenue growth
7.3%
Industry 7.0%
Operating margin
13.5%
Industry 10.1%
Return on equity
11.8%
Industry 7.9%
Free cash flow yield
3.5%
Industry 2.6%

What does Siemens Healthineers do?

Siemens Healthineers develops, manufactures and sells medical technology products and services for diagnostics and therapy. The company is divided into four segments: Imaging (magnetic resonance imaging, computed tomography, X-ray, molecular imaging, ultrasound and software for diagnostic reading), Diagnostics (laboratory and point-of-care diagnostics), Varian (radiation therapy and oncology solutions) and Advanced Therapies (image-guided minimally invasive procedures).

Customers are mainly hospitals, laboratory operators and other healthcare institutions worldwide. Revenue arises both from the sale of equipment and from recurring revenue through service, maintenance, software and consumables such as reagents. In competition, the company is among the globally leading providers in imaging and laboratory diagnostics and competes there with other large medical technology and diagnostics groups. The broad product range, a large installed equipment base and the combination of hardware, software and services form key competitive advantages.

Score profile

Quality5.0
Valuation5.6
Growth3.8
Financial strength3.6
Momentum8.5

Rank vs. Medical Devices (50 companies). 10 = top of the group, 5 = middle. Calculated from the metrics below, without AI.

Metrics compared with the industry

On profitability and quality, Siemens Healthineers ranks in the middle in the group Medical Devices (5.0/10). On growth, the company ranks below average in the group Medical Devices (3.8/10). On valuation (higher = cheaper), the stock ranks in the middle in the group Medical Devices (5.6/10). On financial strength, Siemens Healthineers ranks below average in the group Medical Devices (3.6/10).

MetricStockGroup medianRanking
Forward P/E16.7x19.3xbetter than 63 %
Trailing P/E22.3x26.1xbetter than 67 %
PEG ratio2.2x1.8xbetter than 37 %
EV/EBITDA13.9x17.3xbetter than 67 %
Price/sales2.1x2.9xbetter than 59 %
Price/book2.5x2.5xbetter than 53 %
Revenue growth7.3%7.0%better than 53 %
Earnings growth-0.8%0.0%better than 23 %
Gross margin38.6%59.5%better than 13 %
Operating margin13.5%10.1%better than 61 %
Net margin9.4%5.5%better than 57 %
Return on equity11.8%7.9%better than 70 %
Debt/equity74.0%55.4%better than 34 %
Current ratio1.2x2.5xbetter than 9 %
Free cash flow yield3.5%2.6%better than 66 %
Dividend yield2.3%1.6%–
Payout ratio50.8%38.0%–
Beta0.891.05–

Valuation: what is Siemens Healthineers worth?

Two valuation approaches – a discounted cash flow model and a valuation at the industry’s median multiples – give Siemens Healthineers a model range of 31.97 EUR to 57.16 EUR per share.

Price 43.95 EUR
Analysts 46.74 EUR
Fair value range 31.97 EUR – 57.16 EURMidpoint 50.81 EUR (+15.6% vs. price)

20 analysts, average rating “Buy”, average price target 46.74 EUR (+6.3%).

The full DCF matrix, the reverse DCF (what growth the price implies) and scenarios are part of the Pro analysis.

What the business depends on

  • The willingness of hospitals and healthcare systems to invest largely determines demand for imaging and therapy systems.
  • Recurring revenue from service, software and reagents stabilizes the business and is tied to the installed equipment base.
  • Technological innovation, for example in imaging, radiation therapy and AI-supported software, secures competitiveness and pricing power.

Risks

  • Regulatory requirements, approval procedures and reimbursement decisions can delay product launches and put pressure on prices.
  • Trade conflicts, tariffs and exchange rate fluctuations weigh on a business with a strong international orientation and global supply chains.
  • Government austerity measures and cyclical budget cuts in healthcare can postpone customers' investments in large equipment.

What to look for with Siemens Healthineers

The development of order intake in relation to revenue is informative because it indicates the future capacity utilization of the project-driven equipment business.

Full AI analysis of Siemens Healthineers

The AI evaluates all the numbers above and turns them into an assessment with a score, strengths and weaknesses, a fair value range and risks – from €1.99; Plus (€4.99) adds business model, moat and scenarios, Pro (€9.99) also peer comparison and reverse DCF. See an example.

Analyze a stock

Results in minutes
1 Choose a stock
2 Choose the depth

See what you get first: Example Compact (Apple) PDF Plus example (Microsoft) PDF Example Pro (NVIDIA) PDF

3 Delivery
Secure payment via Stripe Report by email + PDF No subscription

Frequently asked questions about Siemens Healthineers stock

What is the P/E ratio of Siemens Healthineers stock?

Based on expected earnings, Siemens Healthineers trades at a P/E of 16.7x, compared with a median of 19.3x for the peer group Medical Devices. Based on the earnings of the last twelve months it is 22.3x. (data as of Nov 15, 2026)

Does Siemens Healthineers pay a dividend?

Yes. The dividend yield is currently 2.3%, with a payout ratio of 50.8% of earnings.

Is Siemens Healthineers stock undervalued?

Measured by valuation metrics (P/E, EV/EBITDA, price/sales, PEG), Siemens Healthineers is currently valued roughly in line with the average of the companies in the group Medical Devices (valuation score 5.6 out of 10). Our model calculations (DCF and industry multiples) give a range of 31.97 EUR to 57.16 EUR per share at a price of 43.95 EUR. This is a model calculation, not an investment recommendation.

What do analysts say about Siemens Healthineers stock?

20 analysts have an average price target of 46.74 EUR (+6.3% vs. the current price); the average rating is “Buy”. Analyst targets are opinions and change frequently.

Comparable stocks

All information without guarantee. Metrics from public market data, updated daily; company profile written editorially with the help of AI. Not investment advice and not a solicitation to buy or sell securities.